In 1991, he began to discover that humans have “limitations.” In 1998, he pondered on the possibility of combining medicine and engineering to overcome these limitations and began his research on cyborg technology in 2002. He received the Young Investigation Excellence Award from the Robotic Society of Japan in 2011. After working as a research fellow at the Japan Society for the Promotion of Science, he received a Ph.D. degree in robotics and artificial intelligence in 2016. He is responsible for a wide variety of developmental activities, such as circuit and mechanical designing, firmware development, and network system construction.
He has extensive experience in research on the biomimetic robot system and man-machine interfaces using biosignals. He was awarded the Young Award from IEEE Robotics and Automation Society Japan Chapter in 2013 for his achievements in unique mechanism development, which is unconstrained by conventional robotics. He is a specialist in cable-driven mechanisms and traction algorithms and also covers firmware for control systems, software GUI, and analysis software implementation.
After graduating from the University of Tokyo’s Department of Precision Engineering, Ichihashi joined Toshiba Corporation. He was later dispatched to Toshiba America Information Systems, where he was in charge of launching new businesses in the United States. At Toshiba, Ichihashi also served as the head of management planning for an internal company, global sales business manager, and overall reform manager. He later moved to a venture company and worked as the executive director of business operations at ZMP and as CSO executive director at iXs, where he was involved in venture company management. In April 2023, he became a director and COO at MELTIN.Since September of the same year, he has also served as Director and CFO.
After graduating from Keio University’s Faculty of Policy Management, Kitabayashi joined Toshiba Corporation. She was responsible for selling IT systems to numerous customers, including venture firms and large telecommunications companies, as well as launching new businesses. She joined ZMP in 2018 and was involved in establishing a joint venture company related to autonomous driving with partner companies. She later served as the division head and president of a group company. In 2020, she joined iXS and worked as an Alliance Manager in the Strategy & Alliance division, where she was involved in investment negotiations and business partnerships. In 2023, she joined MELTIN and is working to promote its medical business.
Graduated from the Graduate School of Information Science and Technology, Tohoku University, and won the IEEE Robotics and Automation Society Japan Chapter Young Award (2007) in the field of rescue robots while in school. After graduating, he joined Canon Inc., where he worked as a hardware designer to commercialize multiple products, from element development to mass production. Participated in MELTIN from July 2019, involved in element development of MELTIN's first medical device product, MELTz, and carried out the start-up of the factory and mass production. He also drives the development of upcoming products.
After graduating from Toyohashi University of Technology’s Department of Computer Science and Engineering, Shirahata began his career as a software engineer at a Japanese semiconductor company. He joined a software venture firm in 2013 and worked on commissioned development projects for major semiconductor companies. He was also deputy head of the business unit and was involved in a wide range of activities, from development management to business operations. He also served as the head of the personnel department. He joined MELTIN in 2021 and supports MELTIN's business promotion from the field of HR as an HRBP.
He finished the master’s course in Biosphere Science at Hiroshima
University, after which he joined Nippon Steel Corp.
He then worked in drug discovery research in the pharmaceutical
industry and gained experience with drug discovery research and
business planning at Sumitomo Pharmaceutical Co., Ltd. and Daiichi
Pharmaceutical Co., Ltd. Since 2009, he has worked with Sumitomo Pharma Co., Ltd.
He has experience promoting introduction and mergers and acquisitions
(M&A) projects for venture companies using his drug discovery and
business knowledge. he was named director of MELTIN in 2018.In 2022,he was appointed as Director and Managing Executive Officer of Sumitomo Pharma.
He completed a Master’s degree in bioinformatics in 2008 and began a career at Megabank. In 2011, he moved to investment banking as a vice-president and led numerous equity finance and M&A activities. In 2015, he joined Real Tech Fund, a VC with interest in tech ventures in areas such as aerospace and life science, and then MELTIN MMI as an auditor in 2017.
Board Certified physician in Internal medicine and Cardiology. M.S. in Epidemiology from Harvard School of Public Health in 2002. Certificate in General Management Program from Harvard Business School in 2010. He is the first Japanese Medical Officer at the Center for Devices and Radiological Health, US FDA. He is also former Medical Director at Boston Scientific Corporation, and he is a specialist in medical device development. He considers the clinical need for product development. He commercializes medical devices globally by using his wide variety of knowledge and experience from designing the clinical trial through marketing. In 2012 he founded Sanamedi, Inc., Japanese first full-fledged medical incubator, then he joined MELTIN MMI in 2017.
He founded his factory lab in 2008 where he prototypes machines for universities and research institutions. He is responsible for all aspects of production technology.
He finished the master's course of law at Waseda University in 1999
and registered as a lawyer in 2004. He joined in establishing the
Foresight General Law Office in 2011 after gaining experience in a
domestic corporate legal law office. In 2013, he was appointed an
office partner. In addition to many years of providing corporate legal
support for venture companies implementing initial public offerings
(IPOs), he has experience with corporate governance as an outside
officer of several companies. He was named auditor of MELTIN in 2018.
Expertized in concept development, creative direction and producing in art & science and architecture projects. Producing a new generation cultural center "Hakodate Miraikan," art installation "UNITY of MOTION" in Seoul, art pavilion project "KOHTEI" with Kohei Nawa.
(Contemporary artist) and collaborative art & science project "Enceladus" with Tokyo Institute of Technology ELSI (Earth Life Research Institute).
Information Technology Strategist certified by METI.GO.JP. He supported over 100 patents to be granted as Patent Consultant at Tokyo central patent firm. As a Business Producer at Institute of Immunology Co., Ltd., a biotech incubator, he drove research and business development based on the patents in Japan and United States and also involved in conflict resolution of medical devices and antibody drug. After this experience, he joined Astamuse Co., Ltd., the startup from Tokyo University and an open innovation platform provider. In 2015 he joined JOMDD, then he became Medical Device Manager of MELTIN MMI from 2017 for realizing the cyborg technology.
Master of pharmaceutical sciences in Kyoto University graduate school, a registered lawyer since 2005. After a business experience in leading law firm, he went to University of Southern California law school and got masters degree in 2012. He had also done job training in leading law firm in the States. He is now head of lawyer in SHUSAKU·YAMAMOTO, a leading one-stop solution intellectual property, technology and related commercial law firm in Japan. He handles a lot of large-scale or cross-border IPs, and corporate legal works. He became company attorney of MELTIN MMI from 2017.